bearish
Celltrion Has Potential Manufacturing Headaches
461 Views07 Sep 2017 10:09
A Form 483 from the USFDA (attached) that criticizes aspects of Celltrion Inc (068270 KS)'s manufacturing facility in Incheon has surfaced in the...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 1-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
Price Chart(Sign Up to Access)
- The Two Weeks in NorthAsia@Smartkarma That Were: BOJ/N225, Buybacks, & Biosimilars26 Feb 2018
- Biosimilar Battlefield: An Update15 Feb 2018
- Celltrion (068270 KS): Korean Making Biological Drugs for the West05 Jan 2018
- Celltrion Has Potential Manufacturing Headaches07 Sep 2017
- More Discussions on Impacts of Celltrion's KOSPI200 Inclusion23 Aug 2017
- JNJ's REMICADE Holds: PFE's Results To Confirm19 Jul 2017
- The Disconnect Is Growing22 Apr 2017
x